Sepracor Inc.

	Nasdaq: SEPR	Change symbol:

NEWS FROM THE WIRES Sepracor loss widens on higher research spending Jul 23 2001 04:29 AM PDT > More WIRE STORIES about this company  PROFILE For Sepracor, "new and improved" is the name of the game. The company develops and commercializes new, patented forms of existing pharmaceuticals by purging them of nonessential -- or even deleterious -- molecules. Compared to their traditional-compound counterparts, Sepracor's products (called improved chemical entities, or ICEs) can reduce side effects, provide new uses, and improve safety, performance, and dosage. Sepracor focuses its ICE efforts on gastroenterology, neurology, psychiatry, respiratory care, and urology. The firm is also developing its own new drugs to treat infectious diseases and central nervous system disorders.  COMPETITION Barr Laboratories, Inc. (BRL) GlaxoSmithKline plc (GSK) Johnson & Johnson (JNJ)		STOCK ANALYSIS  View by:  Day   Day   Month   Month   Year   Year  FURTHER ANALYSIS • Advanced Charting • Deals  FINANCIAL OVERVIEW Fiscal Year-End: December 2000 Sales (mil.): 85.20 1-Yr. Sales Growth: 275.3% Employees: 499 Revenue per employee: $170,741.48  KEY PEOPLE • Timothy J. Barberich     CEO • David P. Southwell     CFO  CONTACT INFO 111 Locke Dr. Marlborough, MA 01752 US Phone: 508-481-6700 Fax: 508-357-7499 Online: Web Site

	Company Data   News, quotes & more

		Hoover's Company Capsule Copyright © 2001, Hoover's Inc. Austin, Texas. For changes and updates, contact Hoover's directly.